|
AMICUS
Austrian Multicenter Isradipine Cum Spirapril study
 |
Author(s) |
Magometschnigg D
|
 |
Title(s) |
Isradipine in the treatment of mild to moderate hypertension: the Austrian Multicenter Isradipine Cum Spirapril study (AMICUS)
|
|
Reference(s) |
Am J Hypertens 1993;6 Suppl:49S-53S
|
|
Disease |
Mild to moderate hypertension
|
|
Purpose |
To assess the safety and efficacy of isradipine in the treatment of patients with mild to moderate hypertension in general practice
|
|
Study design |
Open
|
|
Follow-up |
26 weeks
|
|
Patients |
595 patients (282 women, 313 men), aged 20-79 years
|
|
Treatment regimen |
Isradipine, 1.25-2.5 mg bid, plus, if necessary, spirapril, 3 mg once daily, or pindolol, 5 mg once daily
|
|
Results |
Normalisation of blood pressure was achieved in 80.5% of cases. This result was obtained with the lower isradipine dose in 249 cases (4.18%), the higher isradipine dose in 215 cases (36.1%) and with isradipine plus spirapril or pindolol in 112 cases (18.5%). There was no clinically relevant change in heart rate. A total of 100 adverse effects were reported in 73 patients (12.3%), of which 18 were severe
|
|
|
|
